Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.32 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | FAAH | O00519 | 1/20 | 0.31 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12523145 | 0.91 | PAOX (0.35) | POLBALDH1A1PKMHDAC3HDAC4 | |
| SCHEMBL19170669 | 0.89 | PAOX (0.41) | POLBALDH1A1GAAHDAC3HDAC4 | |
| SCHEMBL3018585 | 0.88 | PAOX (0.43) | ALDH1A1GAAHDAC3HDAC4HDAC1 | |
| SCHEMBL9943141 | 0.86 | ALDH1A1 (0.34) | POLBALDH1A1PKMBRD4MME | |
| SCHEMBL278538 | 0.86 | POLB (0.34) | POLBALDH1A1PKMGAAHDAC3 | |
| SCHEMBL18515918 | 0.84 | POLB (0.36) | POLBALDH1A1PKMGAACYP19A1 | |
| SCHEMBL19601273 | 0.84 | POLB (0.39) | POLBALDH1A1PKMGAACYP19A1 | |
| SCHEMBL15627254 | 0.83 | ALDH1A1 (0.38) | POLBALDH1A1PKMHDAC3HDAC4 | |
| SCHEMBL18326853 | 0.83 | ALDH1A1 (0.34) | POLBALDH1A1PKMGAAHDAC3 | |
| SCHEMBL22273607 | 0.83 | POLB (0.33) | POLBALDH1A1PKMGAAHDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | MEDIBOSTON LIMITED (HK) | 2024-07-09 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | GENENTECH, INC. (US) | 2023-10-19 | — | — | US | disclosed |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | SEAGEN INC. | 2023-02-02 | — | — | US | disclosed |
| WO-2022165335-A1 | LINKERS FOR IMPROVING THE STABILITY OF BIOCONJUGATES AND THE SELECTIVITY OF PAYLOAD RELEASE | EqIP, LLC (US) | 2022-08-04 | — | — | WO | disclosed |
| US-11352431-B2 | Anti-FCRH5 antibodies | GENENTECH, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-11066459-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | BIOMOLECULAR HOLDINGS LLC (US) | 2021-07-20 | — | — | US | disclosed |
| US-10918735-B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2021-02-16 | — | — | US | disclosed |
| US-20200190185-A1 | ANTI-FCRH5 ANTIBODIES | GENENTECH INC (US) | 2020-06-18 | — | — | US | disclosed |
| US-20190255187-A1 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-08-22 | — | — | US | disclosed |
| US-20120003217-A1 | HERCEPTIN® ADUVANT THERAPY | BRYANT JOHN L (US) | 2012-01-05 | — | — | US | disclosed |
| US-8088378-B2 | Anti-CD79B antibodies and immunoconjugates and methods of use | GENETECH INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20110206658-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | CROWLEY CRAIG | 2011-08-25 | — | — | US | disclosed |
| US-20110142859-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110137017-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | EIGENBROT CHARLES W | 2011-06-09 | — | — | US | disclosed |
| US-7947839-B2 | Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use | GENENTECH, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110070243-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC | CROWLEY CRAIG | 2011-03-24 | — | — | US | disclosed |
| US-7763245-B2 | antibodies that specifically binds ubiquitin comprising a lysine linkage between a lysine residue of one ubiquitin molecule and the C-terminal glycine residue of another ubiquitin molecule | GENENTECH, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | GENENTECH, INC. (US) | 2009-01-29 | — | — | US | disclosed |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | GENENTECH, INC. (US) | 2008-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066459-B2 | Hybrid immunoglobulin containing non-peptidyl linkage | FCGR3B, FCGR2A, SCLY | POLB 4167/4885ALDH1A1 4257/4885PKM 4875/4885 |
| US-20200190185-A1 | ANTI-FCRH5 ANTIBODIES | FCGR3B, FCGRT, FCGR1A | POLB 4336/4885ALDH1A1 2977/4885PKM 4831/4885 |
| US-20230036256-A1 | CAMPTOTHECIN CONJUGATES | DCLRE1A, TOP2A, PAICS | POLB 1017/4885ALDH1A1 1069/4885PKM 4549/4885 |
| US-12029736-B2 | Camptothecin derivatives and conjugates thereof | TOP2A, TOP1, XPA | POLB 2068/4885ALDH1A1 1163/4885PKM 3964/4885 |
| US-20190255187-A1 | SUBSTITUTED PYRAZINO[1',2':1,5]PYRROLO[2,3-B]INDOLE-1,4-DIONES FOR CANCER TREATMENT | IDO1, NPY1R, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | POLB 2727/4885ALDH1A1 548/4885PKM 788/4885 |
| US-20080050310-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | POLB 4774/4885ALDH1A1 404/4885PKM 4840/4885 |
| US-10918735-B2 | Substituted pyrazino[1′,2′:1,5]pyrrolo[2,3-b]indole-1,4-diones for cancer treatment | IDO1, IDO2, INMT | POLB 393/4885ALDH1A1 246/4885PKM 607/4885 |
| US-20110142859-A1 | ANTIBODIES AND IMMUNOCONJUGATES AND USES THEREFOR | CD22, CD2BP2, CD2 | POLB 4774/4885ALDH1A1 404/4885PKM 4840/4885 |
| US-20230330249-A1 | ANTIBODY-CONJUGATED CHEMICAL INDUCERS OF DEGRADATION OF BRM AND METHODS THEREOF | ADRM1, CD79B, BRDT | POLB 2560/4885ALDH1A1 1936/4885PKM 3290/4885 |
| US-20120003217-A1 | HERCEPTIN® ADUVANT THERAPY | ERBB2, BRCA1, HUNK | POLB 1770/4885ALDH1A1 1805/4885PKM 4838/4885 |
| US-20110137017-A1 | CYSTEINE ENGINEERED ANTIBODIES AND CONJUGATES | LNPEP, ALB, GSTP1 | POLB 2127/4885ALDH1A1 382/4885PKM 3988/4885 |
| US-20090028856-A1 | Anti-CD79B Antibodies and Immunoconjugates and Methods of Use | CD99, CD79B, CD47 | POLB 1320/4885ALDH1A1 2554/4885PKM 4738/4885 |
| US-11352431-B2 | Anti-FCRH5 antibodies | FCGR3B, FCGRT, FCGR1A | POLB 4336/4885ALDH1A1 2977/4885PKM 4831/4885 |
| US-20110206658-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN | HCLS1, CD47, MCL1 | POLB 526/4885ALDH1A1 2567/4885PKM 2857/4885 |
| US-20110070243-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC | CD47, HCLS1, MCL1 | POLB 669/4885ALDH1A1 3273/4885PKM 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.